CER Daily Newsfeed

Delivering Real-Time, Data-Driven Insights Across the Evidence Lifecycle

(6/10, The Evidence Base) reports “...At ISPOR 2026, Michael Simonov, MD, Senior Vice President of Product at Truveta, outlined how evidence teams can compress timelines without compromising scientific rigor. This Deep Dive covers the key themes from that session, including: Why data quality, not model sophistication, is the true foundation of trustworthy AI in evidence generation; How human-in-the-loop AI and agentic research systems are changing the operational design of HEOR workflows; Real-world examples from the GLP-1 landscape...” Full

House Appropriations Committee Takes Aim at CMS' WISeR Pilot

(6/9, Paige Minemyer, Fierce Healthcare) reports “...In an amendment added to the broader appropriations bill for the Department of Health and Human Services after a unanimous vote, the House Appropriations Committee determined that ‘none of the funds made available in this Act or any other Act’ should be used to implement the Wasteful and Inappropriate Services Reduction (WISeR) model, or another model that would add prior auth to traditional Medicare. The 2027 appropriations bill will undergo further congressional review on the way to final passage, and was unveiled in its initial form on June 4.” Full

As the U.S. Looks On, European Countries Feel Growing Pressure on Drug Prices

(6/10, Andrew Joseph, STAT+) reports “...In Europe, countries directly negotiate prices with drugmakers, assessing the value that a new medicine delivers versus what’s already on the market. As it is, sometimes companies keep drugs out of a certain market if they feel they’re not being offered a satisfactory price. Now, with the U.S. demanding wealthy European nations pay comparable prices to those it pays — an approach the Trump administration calls ‘most-favored nation,’ or MFN, pricing — the withholding of certain drugs could become all the more common. Companies say they fear that setting or agreeing to lower prices in Europe, as they’ve traditionally done, could tie their hands on pricing in the U.S., their biggest markets by far.” Subscription Required

AMA Endorses Drug Pricing Policies, Not Yet Sold On MFN

(6/9, Gabrielle Wanneh, Inside Health Policy) reports "The American Medical Association committed at its annual House of Delegates meeting this week to backing several administrative and legislative efforts to lower drug prices, including requirements that cash payments insured individuals use to buy drugs through direct-to-consumer platforms count toward their deductibles, but isn't committed to backing international reference pricing efforts like the Trump administration's 'Most Favored Nation' (MFN) policy." Subscription Required

UK: Aquipta Recommended by NICE for Acute Migraine Treatment

(6/10, John Pinching, PharmaTimes) reports “...AbbVie’s Aquipta (atogepant) has been recommended by NICE as an option for the acute treatment of migraine with or without aura in adults, provided patients have previously tried at least two triptans that did not work well enough, or could not take them, and had insufficient response to NSAIDs and paracetamol.” Full

EU JCA: Milestone Report Shows Room For Improvement For Orphan Drugs And PICOs

(6/10, Francesca Bruce, Pink Sheet) reports “...In a major milestone for the EU’s pricing and reimbursement landscape, the European Commission has published the first ever, much anticipated, joint clinical assessment report.” Subscription Required 

Alexion: EU JCAs Could Be A ‘Drag On Competitiveness’ Without Orphan Drug Flexibility

(6/10, Eliza Slawther, Pink Sheet) reports “...Joint clinical assessments in the EU risk becoming a ‘28th assessment’ for drug developers and ‘another drag on EU competitiveness’ if their evidence requirements fail to account for the realities of rare disease drugs, says Alexion’s Soraya Bekkali.” Subscription Required